ASHLEY GRIFFIN: Open Payments
NPI 1942683081 · FRANKLIN, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$725 in 43 payments from 16 companies in 2025. Trend: 2023 $997 · 2024 $643 · 2025 $725
Food & beverage: $725
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $186 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $105 |
| Novo Nordisk Inc | 6 | $91 |
| Amgen Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $50 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| ABBVIE INC. | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Novartis Pharmaceuticals Corporation | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
Products named: Kerendia, XIFAXAN, OTEZLA, CAPLYTA, TRELEGY ELLIPTA, LEQVIO, PURIFIED CORTROPHIN GEL, Rybelsus.
Industry payments across KY — which companies pay providers there.
